Eli Lilly’s (LLY) endocrine products portfolio includes Basaglar, Forteo, Humalog, Jardiance, Humulin, and Trulicity. Its endocrine products also include Glucagon, Humatrope, Actos, Trajenta, and Humapen.
Basaglar, Jardiance, Humalog, Humulin, Trajenta, and Trulicity reported growth in revenues during the first quarter, while the sales for Forteo declined during the quarter. The chart below compares the revenues for key endocrine products since the first quarter of 2017.
Humalog products are the meal-time insulin products from Eli Lilly’s portfolio. Humalog reported revenues of ~$792.0 million during the first quarter, representing 12.0% growth compared to ~$708.0 million during the first quarter of 2017. This growth was driven by strong sales of $504.0 million in the US markets. This growth followed higher realized prices and strong sales of ~$288.0 million in international markets during the quarter.
Humulin products are the company’s concentrated insulin products. Humulin reported revenues of ~$326.0 million during the first quarter, representing 4.0% growth compared to the first quarter of 2017. This growth was driven by strong sales in the US markets, partially offset by lower sales in its international markets. Its sales from the US markets rose 8.0%, and its sales from the international markets decreased 4.0% during the quarter.
Forteo is an osteoporosis drug that reported revenues of ~$313.0 million during the first quarter. This trend represented a 10.0% decline compared to ~$347.0 million during the first quarter of 2017.
This decline was driven by lower sales in its US markets and was partially offset by its growth in international markets. The sales from the US markets fell 31.0%, and the sales from its international markets rose 13.0% during the quarter.
Previously in this series, we discussed the performance of new products from this franchise—Basaglar, Jardiance, and Trulicity.